Showing 6801-6810 of 9958 results for "".
- BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soonhttps://practicaldermatology.com/news/biopharmx-completes-phase-2b-trial-of-bpx-01-topline-results-coming-soon/2458217/BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now plans to announce topline data from the trial in the fi
- Topical Cannabinoids May Soothe Itchy Skinhttps://practicaldermatology.com/news/topical-cannabinoids-may-soothe-itchy-skin/2458218/Cannabinoids contain anti-inflammatory properties that may make them useful in the treatment of a wide-range of skin diseases including eczema, psoriasis, atopic and contact dermatitis, according to researchers at the University of Colorado Anschutz Medical Campus. The new study app
- New “Sonoillumination” Waveguide Device Set to Improve Laser Surgeryhttps://practicaldermatology.com/news/new-sonoillumination-waveguide-device-set-to-improve-laser-surgery/2458221/One of the biggest issues with the lasers used to treat benign vascular birthmarks, port-wine stains and for tattoo removal is making sure the laser light, which is held at a distance from the skin, is perfectly and selectively absorbed by only the targeted birthmark or tattoo. Paul J.D.
- Phase 4 Studies of Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefithttps://practicaldermatology.com/news/phase-4-studies-of-restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit/2458226/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Scary Findings About Common Dermatologic Features of Classic Movie Villainshttps://practicaldermatology.com/news/study-ids-scary-findings-about-common-dermatologic-features-of-classic-movie-villains/2458227/What makes a villain (besides malice)? Scars, warts, deep wrinkles and alopecia, according to a new study that sought to identify the common dermatologic features of classic movie villains including Dr. Hannibal Lecter (“The Silence of the Lambs,” 1991), Mr. Potter (“It&
- Apax Partners To Acquire Syneron for Close to $400 millionhttps://practicaldermatology.com/news/apax-partners-to-acquire-syneron-for-close-to-400-million/2458230/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price repr
- Study: Severe Psoriasis More Common in Menhttps://practicaldermatology.com/news/severe-psoriasis-more-common-in-men/2458235/Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly (p<0.
- 5α-Reductase Inhibitors Not Associated with Increased Suicide Risk in Older Menhttps://practicaldermatology.com/news/5-reductase-inhibitors-not-associated-with-increased-suicide-risk-in-older-men/2458240/Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men, according to new research in JAMA Internal Medicine. Risks f
- Heliocare Spotlights Improved Formulation: Vegan, Gluten-free, and Dye-freehttps://practicaldermatology.com/news/heliocare-spotlights-improved-formulation-vegan-gluten-free-and-dye-free/2458243/Heliocare Daily Use Antioxidant Formula, a clinically proven, natural dietary supplement with antioxidant effects on the skin, has been updated to be vegan, gluten-free, and free of artificial dyes. The once-daily capsules from Ferndale Healthcare, have been recommended by dermatologists fo
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the V